Hcplive
Published October 9, 2026
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia | HCPLive
Read the full story at Hcplive
media/ press - releases . Teva Pharmaceuticals submits NDA on TEV-'749 for schizophrenia to the FDA. HCPLive. https://www.hcplive.com/view/teva.
Surfaced by this Google Alert
- Psychedelic press release